Court Nixes Roxane Labs’s Bid to Enjoin Companies From Selling Competing Generics

Roxane Laboratories Inc. isn’t entitled to a preliminary injunction enjoining other pharmaceutical companies from marketing generic calcium acetate capsules that compete with an identical product made by Roxane, a federal court ruled Aug. 6 (Roxane Labs, Inc. v. Camber Pharm., Inc., D.N.J., 2:14-cv-04042, 8/6/14).

Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey said that Roxane failed to meet the standards for a preliminary injunction. Roxane sued the defendants, Camber Pharmaceuticals Inc. and InvaGen Pharmaceuticals Inc., for infringing its patent directed to a pharmaceutical calcium acetate formulation, and also sought to ...